Understanding the mechanisms that impair anti-tumour Adoptive Cell Therapy

Primary Supervisor Email Number Webpage
Prof Jose Villadangos j.villadangos@unimelb.edu.au

Summary The Villadangos group studies the first event that triggers adaptive immune responses: the presentation of pathogen or tumour antigens to T cells by Dendritic Cells, B cells and Macrophages. We are characterizing the development, regulation and impairment of antigen presenting cells by pathogens, inflammatory mediators and tumours. We are also dissecting the biochemical machinery involved in antigen capture, processing and presentation. We use this knowledge to understand how T cell-dependent immunity is initiated and maintained, and apply it to design better vaccines and immunotherapies against infectious agents and cancer.

Project Details

Tumour cells express neo-antigens that can be recognized by cytotoxic T lymphocytes (CTL). These tumour-specific CTL can be isolated, expanded and inoculated to kill cancer. Unfortunately, in many individuals the tumour ‘fights back’ and inactivates the infused CTL, compromising the therapy. Using a mouse model of lymphoma, we are performing studies to improve outcomes. Our goal is to apply our findings to the clinic and improve the efficacy of adoptive cell therapy. The aims of this project will be to identify genes that control the outcome of adoptive cell therapy, and characterise the interactions between T cells and the tumour.



Key Contact

For further information about this research, please contact a supervisor.


MDHS Research library
Explore by researcher, school, project or topic.